/
CADL
$10.36+$0.57 (+5.82%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$717.3M
73M shares
52-week range
$4.35 – $10.38
100% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
1.45%
Moderate
Price (6 mo)
Loading chart…
Change+$3.36
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $125.0K | $125.0K | $125.0K | $125.0K | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $125.0K | $125.0K | $125.0K | $125.0K | $0 | $0 | $0 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — |
| R&D | $6.6M | $8.8M | $15.2M | $20.8M | $24.5M | $19.3M | $30.5M |
| Operating income | −$9.0M | −$13.8M | −$24.6M | −$34.7M | −$38.4M | −$33.4M | −$48.3M |
| EBITDA | −$8.4M | −$13.1M | −$24.4M | −$16.3M | −$34.4M | −$52.1M | −$35.2M |
| Net income | −$8.2M | −$17.7M | −$36.1M | −$18.8M | −$37.9M | −$55.2M | −$38.2M |
| Net margin | -6592.0% | -14144.0% | -28899.2% | -15035.2% | — | — | — |
| EPS (diluted) | -0.43 | -1.18 | -1.26 | -0.10 | -1.31 | -1.74 | -0.72 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $93M | $-0.92 | $-1.06–$-0.71 | 4 |
| 2027 | $47M | $-0.57 | $-2.44–$1.33 | 3 |
| 2028 | $170M | $0.72 | $-1.42–$4.00 | 5 |
| 2029 | $431M | $3.16 | $3.16–$3.16 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$2.20
Price
$10.36
Implied downside
-79%
Peer comparison
Candel Therapeutics, Inc. Common Stock
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
www.candeltx.com- Employees
- 55
- IPO / List date
- Jul 27, 2021
- HQ
- NEEDHAM, MA
Held by traders on TradeandTell
No one on the platform currently holds CADL.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 12,780 | $62.6K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded CADL yet.
